Weight Loss Results from Clinical Trials
Wegovy (semaglutide 2.4 mg weekly injection) showed average weight reductions of 15-17% over 68 weeks in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities like hypertension or diabetes. In the STEP 1 trial, participants lost 14.9% body weight versus 2.4% on placebo. STEP 2 (with type 2 diabetes) yielded 9.6% loss versus 3.4% placebo. These results held with diet and exercise.[1][2]
How It Compares to Lifestyle Changes Alone
Without medication, diet and exercise typically achieve 5-10% weight loss, often with regain. Wegovy doubled that in trials, with 83% of users losing ≥5% body weight (versus 31% placebo) and 66% losing ≥10%.[1] Long-term data from STEP 5 (2 years) showed sustained 15.2% loss versus 2.6% placebo.[3]
Effectiveness in Specific Groups
- With comorbidities: Reduces cardiovascular risk; SELECT trial (obese without diabetes) cut major events by 20% alongside 9.4% weight loss.[4]
- Type 2 diabetes: STEP 2 showed better A1C control and 6-10% weight loss.
- Adolescents (12-17): Phase 3 trial reported 16.1% loss versus 0.6% placebo over 68 weeks.[5]
Men and women responded similarly, but older adults (>65) had slightly less loss (around 10%).[2]
What Happens After Stopping Wegovy
Most regain two-thirds of lost weight within a year without continued use or lifestyle maintenance, per SUSTAIN trials on similar semaglutide doses.[6] Tapering or switching to lower-dose oral semaglutide may help sustain some loss.
Common Reasons It Might Not Work
About 20% lose <5% weight. Factors include poor adherence (nausea affects 44%), insufficient calorie deficit, or genetic resistance to GLP-1 agonists. Trials excluded those with certain GI disorders.[1][2] Real-world data shows 10-12% average loss at one year, slightly below trials due to dropouts.[7]
Side Effects Impacting Long-Term Use
GI issues (nausea 44%, diarrhea 30%, vomiting 24%) cause 7-16% discontinuation. Rare risks include pancreatitis, gallbladder issues, or thyroid tumors (rodent data). Cardiovascular benefits offset risks for many.[2][4] Patient forums report tolerability improves after 4-8 weeks.
How It Stacks Up Against Other Weight Loss Drugs
| Drug | Avg. Weight Loss (68 weeks) | Key Difference |
|------|-----------------------------|---------------|
| Wegovy | 15% | Highest efficacy; weekly injection |
| Zepbound (tirzepatide) | 21% | Dual GLP-1/GIP; faster loss but more GI effects[8] |
| Saxenda (liraglutide) | 8% | Daily injection; less potent[9] |
| Phentermine | 5-8% (short-term) | Oral; appetite suppressant, not for long-term[10] |
Wegovy outperforms older drugs but trails dual-agonists like Zepbound in head-to-head potential.
Sources
[1] NEJM: STEP 1 Trial (2021) https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[2] Novo Nordisk Prescribing Info https://www.wegovy.com
[3] NEJM: STEP 5 (2022) https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
[4] NEJM: SELECT Trial (2023) https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
[5] NEJM: Adolescent Trial (2022) https://www.nejm.org/doi/full/10.1056/NEJMoa2202785
[6] Diabetes Care: SUSTAIN Weight Regain (2021)
[7] JAMA: Real-World Semaglutide (2023) https://jamanetwork.com/journals/jama/fullarticle/2802738
[8] NEJM: SURMOUNT-1 (Zepbound) (2022) https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
[9] NEJM: SCALE Trial (Saxenda) (2015)
[10] FDA Label: Phentermine